China’s Ivonescimab Outperforms Keytruda in Late-Stage Cancer Trials
Chinese-developed cancer drug Ivonescimab surpasses Keytruda in Phase III trials, signaling potential shift in global oncology treatment standards.
ChinaBiotech
Read More
News & Insights Across Asia